Big bucks riding on FDA's little dosing decision for indacaterol (NEJM)
www.pulmccm.org
In July 2011, FDA approved indacaterol, Novartis's new once-daily long-acting beta agonist, for the treatment of chronic obstructive pulmonary disease. In contrast to its European counterpart (EMA), which approved indacaterol there at doses up to 300 mcg, FDA only approved indacaterol in the
Big bucks riding on FDA's little dosing decision for indacaterol (NEJM)
Big bucks riding on FDA's little dosing…
Big bucks riding on FDA's little dosing decision for indacaterol (NEJM)
In July 2011, FDA approved indacaterol, Novartis's new once-daily long-acting beta agonist, for the treatment of chronic obstructive pulmonary disease. In contrast to its European counterpart (EMA), which approved indacaterol there at doses up to 300 mcg, FDA only approved indacaterol in the